Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 73Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Burkitt Lymphoma 25Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Recurrence 8Immunoglobulin Light-chain Amyloidosis 8Vomiting 7Nausea 7Lymphoma, Mantle-Cell 7Leukemia, Biphenotypic, Acute 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasms 5Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 5Leukemia 5Hodgkin Disease 5Smoldering Multiple Myeloma 4Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Lung Neoplasms 4Breast Neoplasms 4Blast Crisis 4Prostatic Neoplasms 3Plasmacytoma 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Lenalidomide 2Dexamethasone 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × POEMS Syndrome × dexamethasone acetate × Clear all
NCT02921893 2025-02-12

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Mayo Clinic

Phase EARLY_PHASE1 Completed
21 enrolled
Plasma cell

Plasmacytoma, POEMS Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡